3986 related articles for article (PubMed ID: 32588816)
1. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
[TBL] [Abstract][Full Text] [Related]
4. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
[TBL] [Abstract][Full Text] [Related]
7. The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.
Guthrie B; Rogers G; Livingstone S; Morales DR; Donnan P; Davis S; Youn JH; Hainsworth R; Thompson A; Payne K
Health Soc Care Deliv Res; 2024 Feb; 12(4):1-275. PubMed ID: 38420962
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
[TBL] [Abstract][Full Text] [Related]
9. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
10. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
Burch J; Rice S; Yang H; Neilson A; Stirk L; Francis R; Holloway P; Selby P; Craig D
Health Technol Assess; 2014 Feb; 18(11):1-180. PubMed ID: 24534414
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for steroid-induced osteoporosis.
Allen CS; Yeung JH; Vandermeer B; Homik J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
[TBL] [Abstract][Full Text] [Related]
14. Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.
Claxton L; Simmonds M; Beresford L; Cubbon R; Dayer M; Gottlieb SS; Hartshorne-Evans N; Kilroy B; Llewellyn A; Rothery C; Sharif S; Tierney JF; Witte KK; Wright K; Stewart LA
Health Technol Assess; 2022 Jan; 26(4):1-128. PubMed ID: 35076012
[TBL] [Abstract][Full Text] [Related]
15. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.
Kanis JA; Stevenson M; McCloskey EV; Davis S; Lloyd-Jones M
Health Technol Assess; 2007 Mar; 11(7):iii-iv, ix-xi, 1-231. PubMed ID: 17311734
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.
Brazzelli M; Aucott L; Aceves-Martins M; Robertson C; Jacobsen E; Imamura M; Poobalan A; Manson P; Scotland G; Kaye C; Sawhney S; Boyers D
Health Technol Assess; 2022 Jan; 26(7):1-286. PubMed ID: 35115079
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]